Webinar being held today "Evolving strategic context for phages, Introducing new opportunities" to present PHAXIAM Therapeutics strategyBased on the positive evolution in phages therapy market, PHAXIAM’s development strategy could allow the Company to reach operating profitability and positive free cash flow in 2027 Lyon (France) – November 27, 2024, at 02:30 p.m. CET – PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant ...

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day" This event, organized in collaboration with Phage Canada and bringing together international experts, highlighted the growing interest in phage therapy and the urgent need for a reference method for phagogram on an international scalePHAXIAM phages demonstrated outstanding performance against clinical bacterial strains Lyon (France) – November 18, 2024, at 06:00 p.m. CET – PHAXIAM Therapeutics (Eu ...

Cash and cash equivalents of €5.7 million as of September 30, 2024Execution of clinical strategy as planned, with the GLORIA global Phase II study initiation expected in the first quarter of 2025 Lyon (France), November 13, 2024, at 5:45 p.m. CET – PHAXIAM Therapeutics (Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today reports its financial results for the third quarter of 2024. "The third quarter of 2024 was marked by the stea ...

GLORIA, the world's 1st phase II phage therapy study in the treatment of Prosthetic Joint Infections (PJI) related to Staphylococcus aureusThe clinical protocol also being submitted to the European health authorities and the MHRA in the UKPatients recruitment scheduled to start in Q1 2025 for clinical data readout expected in Q3 2026 Lyon (France), November 04, 2024 – 6:00 pm CET - PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company developing innovative treatments for severe a ...

文章核心观点 - PHAXIAM Therapeutics 致力于成为全球领先的噬菌体疗法公司，专注于治疗严重和耐药性细菌感染。公司的发展战略明确，目标是在2024年底前提交GLORIA二期研究的IND和CTA申请，并在2025年第一季度启动全球二期研究。[1][2][3][4][5][6][7][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28] 业务亮点 - 公司专注于高价值治疗领域，特别是针对严重耐药性感染的患者，这些感染与高死亡率和医疗预算影响相关。[3] - 公司在2024年取得了显著进展，加速了其战略部署，特别是在针对由金黄色葡萄球菌（S. aureus）引起的假体关节感染（PJI）的领先项目上。[3] - 公司计划在2024年底前提交GLORIA二期研究的IND和CTA申请，并在2025年第一季度启动全球二期研究。[6][7] - 公司正在进行的临床研究包括针对耐药性金黄色葡萄球菌感染的心内膜炎（EI）和复杂单细菌大肠杆菌（E. coli）感染的研究。[8][9] - 公司已治疗超过120名患者，其中大部分患有髋关节或膝关节PJI，显示出约80%的3个月感染控制率，显著优于标准治疗。[10][11] - 公司计划在2025年初提交针对耐药性铜绿假单胞菌（P. aeruginosa）感染的早期访问计划（AAC）申请。[12] - 公司还参与了两项由研究者发起的临床试验，分别针对糖尿病足溃疡（DFU）和复杂尿路感染（cUTI）。[13] 财务结果 - 2024年上半年，公司运营费用为1175万欧元，比去年同期减少了7%。[17] - 公司研发费用增加了140万欧元（+41%），主要用于S. aureus开发项目。[18] - 截至2024年6月30日，公司现金及现金等价物为150万欧元，比2023年底减少了900万欧元。[19] - 2024年7月，公司通过资本增加获得了680万欧元的净收益，增加了现金储备。[20] - 公司预计现有现金储备足以支持其现有项目和预期运营费用至2025年3月。[21] 管理团队 - 公司首席财务官/首席运营官Eric Soyer离职，由Frédéric Mathat接任首席财务官。[22][23] 未来12个月的关键新闻和里程碑 - 预计在2024年第四季度启动糖尿病足溃疡（DFU）二期研究的首位患者入组。[24] - 预计在2024年底前公布PhagoDAIR试点研究的临床数据。[24] - 预计在2024年第四季度获得GLORIA全球二期研究的IND和CTA批准。[24] - 预计在2025年第一季度启动GLORIA全球二期研究的首位患者入组。[24] - 预计在2025年年中公布心内膜炎一期PK研究的首批临床结果。[24]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________ FORM 6-K ________________________ REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-38281 ________________________ PHAXIAM Therapeutics S.A. (Translation of registrant’s name into English) ________________________ 60 Avenue Rockefeller 69008 Lyon France (Address of principal executive office) _______ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________ FORM 20-F ________________________ (Mark One) ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from____________to ...